Get the Stockscreener App
0.8879
4.01%
0.0342
After Hours:
.86
-0.0279
-3.14%
Jaguar Health Inc stock is traded at $0.8879, with a volume of 924.76K.
It is up +4.01% in the last 24 hours and up +25.93% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
See More
Previous Close:
$0.8537
Open:
$0.858
24h Volume:
924.76K
Relative Volume:
0.27
Market Cap:
$3.71M
Revenue:
$10.48M
Net Income/Loss:
$-37.74M
P/E Ratio:
-0.0549
EPS:
-16.1846
Net Cash Flow:
$-29.03M
1W Performance:
+45.80%
1M Performance:
+25.93%
6M Performance:
-49.84%
1Y Performance:
-93.83%
1-Day Range:
$0.81
$0.9221
1-Week Range:
$0.59
$0.9221
52-Week Range:
$0.56
$15.75
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
0.8879 | 3.56M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
Is Jaguar Health Inc stock showing strong momentumJuly 2025 Action & Real-Time Sentiment Analysis - baoquankhu1.vn
Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates - The Coloradoan
JAGX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference - 富途牛牛
Jaguar Health (JAGX) Announces Special Stock Dividend with Conve - GuruFocus
Jaguar Declares Special Stock Dividend to Protect Shareholders - Intellectia AI
Jaguar Health Declares Special Convertible Preferred Stock Dividend - TipRanks
Jaguar Health to Pay Special Stock Dividend - marketscreener.com
Jaguar Health Announces a Special One-time Stock Dividend - ACCESS Newswire
Hedge Fund Moves: Should value investors consider Jaguar Health IncJuly 2025 Volume & AI Driven Stock Price Forecasts - baoquankhu1.vn
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Treasure Coast News
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, March 6th, During the Western Veterinary Conference (WVC) in Las Vegas - ACCESS Newswire
Is Jaguar Health Inc. stock a safe buy before earningsQuarterly Investment Review & AI Based Trade Execution Alerts - mfd.ru
Will Jaguar Health Inc. benefit from current market trendsGap Up & Low Risk Investment Opportunities - mfd.ru
Bull Bear: Is Howard Hughes Holdings Inc a cyclical or defensive stockJuly 2025 Final Week & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Is Jaguar Health Inc. undervalued by DCF analysisWeekly Trade Summary & High Win Rate Trade Tips - mfd.ru
Is Jaguar Health Inc. stock showing strong momentum2025 Big Picture & Weekly High Return Stock Opportunities - mfd.ru
Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): BUY - TradingView
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million - Marco Eagle
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts - The Marion Star
Should value investors consider Jaguar Health Inc.July 2025 Opening Moves & Weekly Breakout Watchlists - mfd.ru
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue - hattiesburgamerican.com
Jaguar Health Executes Debt-Reducing Equity Warrant Transactions - TipRanks
Jaguar Health Signs Multiple Material Agreements - TradingView
Jaguar Health (JAGX) Advances Rare Disease Program with Focus on Crofelemer - GuruFocus
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi - Lansing State Journal
Jaguar trial cuts children’s IV support needs by up to 37% - Stock Titan
Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - barnstablepatriot.com
Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - Pueblo Chieftain
Earnings Report: Is Jaguar Health Inc a defensive stock2025 Valuation Update & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):